Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors. (February 2017)

• Record Type: Journal Article
• Authors: Ter‐Minassian, Monica; Zhang, Sui; Brooks, Nichole V.; Brais, Lauren K.; Chan, Jennifer A.; Christiani, David C.; Lin, Xihong; Gabriel, Sylvie; Dinet, Jérôme; Kulke, Matthew H.
• Is Part Of: Oncologist. Volume 22:Number 2(2017)
• Page Start: 165
• Page End: 172
• Publication Date: 2017-02
• Subjects: Neuroendocrine tumors -- Somatostatin analogs -- Progression‐free survival -- Overall survival -- Landmark analysis; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2016-0175
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Endpoints related to tumor progression are commonly used in clinical trials of novel therapeutic agents for neuroendocrine tumors (NETs). Whether improved tumor control translates into improved overall survival (OS), however, is uncertain. We assessed associations between tumor progression endpoints and OS in observational cohorts of patients with advanced neuroendocrine tumors treated with somatostatin analogs or with everolimus. We identified 440 patients with advanced NET who had received treatment with single‐agent somatostatin analogs and 109 patients treated with everolimus, all of whom were treated at our institution and were evaluable for both tumor progression and survival. We assessed associations between progression‐free survival (PFS) and OS by using the Kendall tau test, and we assessed associations between tumor progression and OS by using a landmark analysis. In the 440 patients treated with somatostatin analogs, we observed a significant correlation between PFS and OS by using the Kendall tau test (0.31; p < .0001). Additionally, the development of progressive disease was associated with OS in a landmark analysis, at landmark times of 6, 12, 18, and 24 months. In the 109 patients treated with everolimus, we similarly observed a significant correlation between PFS and OS by using the Kendall tau test (0.44; p < .0001) and associations between progressive disease and OS by using a landmark analysis at 3, 6, and 12 months. In these observational cohorts of patients with metastatic NET treated with single‐agent somatostatin analogs or everolimus, longer times to disease progression and longer PFS were both associated with improved OS. Our findings support the continued use of disease progression endpoints in NET clinical trials. Implications for Practice: Clinical trials in patients with advanced neuroendocrine tumors have used progression‐free survival as a primary endpoint. While there is a general assumption that slowing or halting tumor growth is beneficial, little direct evidence links improvements in progression endpoints to improvements in overall survival. This study assessed associations between tumor progression endpoints and overall survival in observational cohorts of patients with advanced neuroendocrine tumor treated with somatostatin analogs or everolimus. Longer times to disease progression and improved progression‐free survival were both associated with improved overall survival. The findings support the continued use of tumor progression endpoints in clinical trials for neuroendocrine tumors. Abstract : In observational cohorts of patients with metastatic neuroendocrine tumor (NET) treated with single‐agent somatostatin analogs or everolimus, longer times to disease progression and longer progression‐free survival were both associated with improved overall survival. These findings support the continued use of disease progression endpoints in NET clinical trials.